艾德生物(300685) - 2020 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders was ¥45,325,881.41, representing a growth of 47.67% year-on-year[8]. - Operating revenue for the period was ¥200,992,255.39, reflecting a year-on-year increase of 37.15%[8]. - The total comprehensive income for the current period was ¥45,226,283.10, compared to ¥30,809,796.11 in the previous period, representing an increase of approximately 47%[65]. - Total operating revenue for the current period reached ¥484,020,471.55, an increase of 17.4% compared to ¥412,461,054.84 in the previous period[73]. - Net profit for the current period was ¥117,697,122.80, up from ¥95,878,043.64 in the previous period, reflecting a growth of approximately 22.8%[87]. - The total profit for the current period was ¥144,044,330.44, compared to ¥128,698,575.48, an increase of 11.8%[76]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,227,079,171.46, an increase of 17.22% compared to the end of the previous year[8]. - Current liabilities totaled ¥162,331,932.55, an increase from ¥140,567,109.42, reflecting a rise of about 15.5%[45]. - Total liabilities reached ¥169,522,469.08, up from ¥144,668,919.90, marking an increase of around 17.1%[45]. - Owner's equity totaled ¥1,057,556,702.38, compared to ¥902,105,138.07, reflecting an increase of approximately 17.3%[48]. - The company's total liabilities were ¥140,567,109.42, consistent with the previous reporting period[107]. Cash Flow - The net cash flow from operating activities was ¥59,989,170.46, up by 13.89% compared to the same period last year[8]. - Cash received from operating activities rose by 96.46% to ¥44,680,816.13, mainly due to increased government subsidies[29]. - Cash flow from operating activities was ¥149,300,432.53, compared to ¥134,307,958.21 in the previous period, showing an increase of approximately 11.2%[93]. - Net cash flow from operating activities was ¥122,530,438.39, up from ¥110,768,247.55, reflecting a growth of 10.4%[97]. - The company reported a net cash outflow from investment activities of ¥213,649,923.74, worsening from a net outflow of ¥108,310,815.37 in the previous period[93]. Shareholder Information - The total number of shareholders at the end of the reporting period was 16,809[14]. - The largest shareholder, Foresee Investment (Hong Kong) Co., Ltd., held 22.95% of the shares[14]. - The top 10 shareholders hold a total of 50,942,520 shares, representing a significant portion of the company's equity[20]. - The company has no preferred shareholders as indicated in the report[21]. - The company has not reported any financing or margin trading activities among its top shareholders during the reporting period[20]. Research and Development - Research and development expenses grew by 32.31% to ¥86,512,568.40, driven by increased costs for R&D materials and personnel[27]. - Research and development expenses for the current period were ¥86,512,568.40, up from ¥65,386,986.38, indicating a growth of 32.3%[76]. - Research and development expenses increased to ¥72,864,944.96 from ¥58,676,222.43, marking a rise of about 24.1%[84]. Government Subsidies - The company recorded government subsidies amounting to ¥23,784,026.41 during the reporting period[9]. - The company reported a 63.66% increase in other income, totaling ¥23,784,026.41, primarily from government subsidies[27]. Inventory and Receivables - Accounts receivable rose by 129.76% to ¥2,511,507.73, attributed to an increase in bank acceptance bill settlements for sales[27]. - Inventory increased by 112.05% to ¥36,392,133.08, mainly due to higher procurement of raw materials[27]. - Accounts receivable increased to ¥270,189,804.29 from ¥229,612,373.08, showing a growth of approximately 17.7%[49]. Financial Position - The company has a total of 123 core management and technical personnel eligible for stock incentives after accounting for departures[24]. - The company has a capital reserve of CNY 437,032,877.21, which supports future growth initiatives[120]. - The company has an unallocated profit of CNY 328,228,215.75, contributing to retained earnings[120].